China Pharma (NYSE: CPHI) raises $5M in registered direct sale
Rhea-AI Filing Summary
China Pharma Holdings, Inc. agreed on July 22, 2026 to sell 2,500,000 shares of common stock in a registered direct offering to an institutional accredited investor at $2.00 per share, for aggregate gross proceeds of $5,000,000, with closing expected on or around July 23, 2026.
The investor receives a right to participate in up to 40% of subsequent financings for three months after closing, while the company agrees for 91 days not to enter into subsequent placements or variable rate transactions, subject to exceptions. FT Global Capital, Inc. acts as exclusive placement agent and will receive a 7.0% cash commission on proceeds, plus a similar commission on qualifying financings with its contacted investors for 18 months after the placement agency agreement ends. The company plans to use net proceeds for working capital and general corporate purposes under an effective shelf registration statement (File No. 333-276481).
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 1.01, 8.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares offered: 2,500,000 shares
Offering price: $2.00 per share
Gross proceeds: $5,000,000
+4 more
7 metrics
Shares offered
2,500,000 shares
Common stock in registered direct offering
Offering price
$2.00 per share
Purchase price in registered direct offering
Gross proceeds
$5,000,000
Aggregate gross proceeds before placement agent fees and expenses
Placement agent commission
7.0%
Cash fee on aggregate proceeds to FT Global Capital, Inc.
Investor participation right
40%
Right to participate in subsequent financings for three months after closing
Restriction period
91 days
No subsequent placements or variable rate transactions after closing, subject to exceptions
Tail commission period
18 months
Period FT Global may earn commission on certain later financings
Key Terms
registered direct offering, Variable Rate Transaction, shelf registration statement, Emerging growth company
4 terms
registered direct offering regulatory
"agreed to issue and the Investor agreed to purchase, in a registered direct offering"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
Variable Rate Transaction regulatory
"the Company will not enter into an agreement to effect a “Variable Rate Transaction”"
shelf registration statement regulatory
"offered by the Company pursuant to an effective shelf registration statement"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stock offering did China Pharma Holdings (CPHI) announce on July 22, 2026?
China Pharma agreed to sell 2,500,000 common shares in a registered direct offering at $2.00 per share, for $5,000,000 in gross proceeds to an institutional accredited investor, with closing expected around July 23, 2026.
How will China Pharma Holdings (CPHI) use the proceeds from the July 2026 offering?
China Pharma intends to use the net proceeds from the $5,000,000 offering for working capital and general corporate purposes, supporting its ongoing operations and financial flexibility following the July 22, 2026 securities purchase agreement.
What participation rights did the investor receive in China Pharma’s (CPHI) July 2026 financing?
The institutional investor obtained the right to participate in up to 40% of China Pharma’s subsequent financings, on the same terms, for three months after the closing date of the July 2026 registered direct offering.
What lock-up and variable rate restrictions apply to China Pharma (CPHI) after the July 2026 deal?
From signing until the 91st day after closing, China Pharma agreed not to enter into Subsequent Placements or agreements for Variable Rate Transactions, subject to specified exceptions in the securities purchase agreement.
What compensation will FT Global receive in China Pharma’s (CPHI) July 2026 offering?
FT Global Capital, Inc. will receive a 7.0% cash commission on aggregate proceeds from the offering and may earn the same commission on qualifying financings with investors it contacted for up to 18 months after the placement agency agreement ends.
Under which registration statement was China Pharma’s (CPHI) July 2026 offering made?
The shares are being sold under an effective shelf registration statement, File No. 333-276481, which was declared effective on February 14, 2024, enabling the registered direct offering described on July 22, 2026.